CA2913512A1 - Procedes et compositions pour detecter une perte auditive progressive - Google Patents

Procedes et compositions pour detecter une perte auditive progressive Download PDF

Info

Publication number
CA2913512A1
CA2913512A1 CA2913512A CA2913512A CA2913512A1 CA 2913512 A1 CA2913512 A1 CA 2913512A1 CA 2913512 A CA2913512 A CA 2913512A CA 2913512 A CA2913512 A CA 2913512A CA 2913512 A1 CA2913512 A1 CA 2913512A1
Authority
CA
Canada
Prior art keywords
seq
foxl1
mutation
nucleotides
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2913512A
Other languages
English (en)
Inventor
Terry-Lynn Young
Nelly ABDELFATAH
Anne GRIFFIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial University of Newfoundland
Original Assignee
Memorial University of Newfoundland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial University of Newfoundland filed Critical Memorial University of Newfoundland
Publication of CA2913512A1 publication Critical patent/CA2913512A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/14—Disorders of ear, nose or throat
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
CA2913512A 2013-05-30 2014-05-30 Procedes et compositions pour detecter une perte auditive progressive Abandoned CA2913512A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829050P 2013-05-30 2013-05-30
US61/829,050 2013-05-30
PCT/CA2014/000471 WO2014190422A1 (fr) 2013-05-30 2014-05-30 Procédés et compositions pour détecter une perte auditive progressive

Publications (1)

Publication Number Publication Date
CA2913512A1 true CA2913512A1 (fr) 2014-12-04

Family

ID=51987804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2913512A Abandoned CA2913512A1 (fr) 2013-05-30 2014-05-30 Procedes et compositions pour detecter une perte auditive progressive

Country Status (3)

Country Link
CA (1) CA2913512A1 (fr)
GB (1) GB2529585A (fr)
WO (1) WO2014190422A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586006B2 (en) * 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use

Also Published As

Publication number Publication date
GB201520366D0 (en) 2016-01-06
GB2529585A (en) 2016-02-24
WO2014190422A1 (fr) 2014-12-04

Similar Documents

Publication Publication Date Title
US11035003B2 (en) TRPC6 involved in glomerulonephritis
KR101828290B1 (ko) 자궁내막암 마커
US20210025004A1 (en) Compositions and methods for determining genetic polymorphisms in the tmem216 gene
CN106460054A (zh) 癌症中的融合基因
JP4436800B2 (ja) Ｌｍｎａ遺伝子、ならびにハッチンソン−ギルフォード早老症候群（ｈｇｐｓ）および動脈硬化におけるその関与
EP1854881B1 (fr) PROCEDES D'IDENTIFICATION D'UN GENE Corl2 CIBLANT LES CELLULES DE PURKINJE
CA2852631A1 (fr) Un gene et ses mutations associees a une crise d'epilepsie et a des troubles moteurs
CA2913512A1 (fr) Procedes et compositions pour detecter une perte auditive progressive
WO2015194524A1 (fr) Nouveau gène chimère de la leucémie lymphoblastique aiguë à précurseurs b
US9624544B2 (en) Allelic disorders caused by mutations in TRPV4
WO2005001127A1 (fr) Le p53 indicateur de risques de cancer dans differents groupes ethniques
KR20210141130A (ko) 샤르코-마리-투스병 진단용 마커 및 그의 용도
Frosk Limb girdle muscular dystrophy in the Hutterite population of Manitoba
KR20190083801A (ko) 데스모글레인 3의 유전적 변이 및 이의 용도
Class et al. Patent application title: Diagnosis of Hereditary Spastic Paraplegias (HSP) by Identification of a Mutation in the ZFVYE26 Gene or Protein Inventors: Institut National De La Sante Et De La Recherche (Paris-Cedex, FR) Giovanni Stevanin (Paris, FR) Sylvain Hanein (Paris, FR) Amir Boukhris (Paris, FR) Cyril Goizet (Paris, FR) Elodie Martin (Paris, FR) Alexis Brice (Paris, FR) Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM)
VanHouten MIPP, an actin-binding protein often ectopically expressed in BALB/c mouse mammary carcinomas, is associated with the endoplasmic reticulum, and inhibits extracellular matrix-induced mammary structure formation in vitro
JP2007526763A (ja) 新規のヌクレオチドおよびアミノ酸配列、ならびにそれらを心臓疾患の診断に用いるアッセイおよび方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831